Prognostic relevance of altered Fas (CD95)-system in human breast cancer

Marcella Mottolese, Simonetta Buglioni, Carla Bracalenti, Marco Andrea Cardarelli, Luciana Ciabocco, Diana Giannarelli, Claudio Botti, Pier Giorgio Natali, Antonio Concetti, Franco Maria Venanzi

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

The Fas ligand (FasL) and its receptor Fas (APO-I or CD95) are members, respectively, of the tumor necrosis factor family that, upon interaction with each other, play a key role in the initiation of one apoptotic pathway. Faulty regulation of the Fas system has been described in a variety of human tumors with different histogenetic origin. Here, we describe the expression and distribution of Fas receptor and ligand pair antigens in surgical samples collected from a cohort of 186 patients bearing breast neoplasms (45 benign and 141 malignant lesions). Immunoperoxidase staining of formalin-fixed tissues showed that 91.1% of benign lesions expressed Fas, which was present in only 56.7% of malignant tumors. On the other hand, FasL was found positive in 22.2% of benign neoplasms and up-regulated in in situ as well as invasive carcinomas (53.9%). Moreover, in malignant tumors, the expression of receptor and ligand antigens appeared to be inversely related. When these findings were correlated with pathological parameters of prognostic relevance, a significant association was observed between FasL and the presence of metastatic lymph nodes and larger tumor size while Fas expression correlated to node-negative status and smaller tumor size. Patients with Fas positive tumors exhibited longer disease-free survival than those with Fas-negative carcinoma while FasL did not influence patient outcome. These relationships indicate that benign and malignant mammary lesions are characterized by differential cellular expression of Fas and FasL and suggest that a neoplastic Fas negative/FasL positive phenotype may be linked to breast cancer progression. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)127-132
Number of pages6
JournalInternational Journal of Cancer
Volume86
Issue number3
Publication statusPublished - 2000

Fingerprint

Fas Ligand Protein
Breast Neoplasms
Neoplasms
CD95 Antigens
Carcinoma
Antigen Receptors
Formaldehyde
Disease-Free Survival
Breast
Tumor Necrosis Factor-alpha
Lymph Nodes
Staining and Labeling
Ligands
Phenotype
Antigens

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mottolese, M., Buglioni, S., Bracalenti, C., Cardarelli, M. A., Ciabocco, L., Giannarelli, D., ... Venanzi, F. M. (2000). Prognostic relevance of altered Fas (CD95)-system in human breast cancer. International Journal of Cancer, 86(3), 127-132.

Prognostic relevance of altered Fas (CD95)-system in human breast cancer. / Mottolese, Marcella; Buglioni, Simonetta; Bracalenti, Carla; Cardarelli, Marco Andrea; Ciabocco, Luciana; Giannarelli, Diana; Botti, Claudio; Natali, Pier Giorgio; Concetti, Antonio; Venanzi, Franco Maria.

In: International Journal of Cancer, Vol. 86, No. 3, 2000, p. 127-132.

Research output: Contribution to journalArticle

Mottolese, M, Buglioni, S, Bracalenti, C, Cardarelli, MA, Ciabocco, L, Giannarelli, D, Botti, C, Natali, PG, Concetti, A & Venanzi, FM 2000, 'Prognostic relevance of altered Fas (CD95)-system in human breast cancer', International Journal of Cancer, vol. 86, no. 3, pp. 127-132.
Mottolese, Marcella ; Buglioni, Simonetta ; Bracalenti, Carla ; Cardarelli, Marco Andrea ; Ciabocco, Luciana ; Giannarelli, Diana ; Botti, Claudio ; Natali, Pier Giorgio ; Concetti, Antonio ; Venanzi, Franco Maria. / Prognostic relevance of altered Fas (CD95)-system in human breast cancer. In: International Journal of Cancer. 2000 ; Vol. 86, No. 3. pp. 127-132.
@article{80c67a30a8174a40a3ae47053738f26c,
title = "Prognostic relevance of altered Fas (CD95)-system in human breast cancer",
abstract = "The Fas ligand (FasL) and its receptor Fas (APO-I or CD95) are members, respectively, of the tumor necrosis factor family that, upon interaction with each other, play a key role in the initiation of one apoptotic pathway. Faulty regulation of the Fas system has been described in a variety of human tumors with different histogenetic origin. Here, we describe the expression and distribution of Fas receptor and ligand pair antigens in surgical samples collected from a cohort of 186 patients bearing breast neoplasms (45 benign and 141 malignant lesions). Immunoperoxidase staining of formalin-fixed tissues showed that 91.1{\%} of benign lesions expressed Fas, which was present in only 56.7{\%} of malignant tumors. On the other hand, FasL was found positive in 22.2{\%} of benign neoplasms and up-regulated in in situ as well as invasive carcinomas (53.9{\%}). Moreover, in malignant tumors, the expression of receptor and ligand antigens appeared to be inversely related. When these findings were correlated with pathological parameters of prognostic relevance, a significant association was observed between FasL and the presence of metastatic lymph nodes and larger tumor size while Fas expression correlated to node-negative status and smaller tumor size. Patients with Fas positive tumors exhibited longer disease-free survival than those with Fas-negative carcinoma while FasL did not influence patient outcome. These relationships indicate that benign and malignant mammary lesions are characterized by differential cellular expression of Fas and FasL and suggest that a neoplastic Fas negative/FasL positive phenotype may be linked to breast cancer progression. (C) 2000 Wiley-Liss, Inc.",
author = "Marcella Mottolese and Simonetta Buglioni and Carla Bracalenti and Cardarelli, {Marco Andrea} and Luciana Ciabocco and Diana Giannarelli and Claudio Botti and Natali, {Pier Giorgio} and Antonio Concetti and Venanzi, {Franco Maria}",
year = "2000",
language = "English",
volume = "86",
pages = "127--132",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Prognostic relevance of altered Fas (CD95)-system in human breast cancer

AU - Mottolese, Marcella

AU - Buglioni, Simonetta

AU - Bracalenti, Carla

AU - Cardarelli, Marco Andrea

AU - Ciabocco, Luciana

AU - Giannarelli, Diana

AU - Botti, Claudio

AU - Natali, Pier Giorgio

AU - Concetti, Antonio

AU - Venanzi, Franco Maria

PY - 2000

Y1 - 2000

N2 - The Fas ligand (FasL) and its receptor Fas (APO-I or CD95) are members, respectively, of the tumor necrosis factor family that, upon interaction with each other, play a key role in the initiation of one apoptotic pathway. Faulty regulation of the Fas system has been described in a variety of human tumors with different histogenetic origin. Here, we describe the expression and distribution of Fas receptor and ligand pair antigens in surgical samples collected from a cohort of 186 patients bearing breast neoplasms (45 benign and 141 malignant lesions). Immunoperoxidase staining of formalin-fixed tissues showed that 91.1% of benign lesions expressed Fas, which was present in only 56.7% of malignant tumors. On the other hand, FasL was found positive in 22.2% of benign neoplasms and up-regulated in in situ as well as invasive carcinomas (53.9%). Moreover, in malignant tumors, the expression of receptor and ligand antigens appeared to be inversely related. When these findings were correlated with pathological parameters of prognostic relevance, a significant association was observed between FasL and the presence of metastatic lymph nodes and larger tumor size while Fas expression correlated to node-negative status and smaller tumor size. Patients with Fas positive tumors exhibited longer disease-free survival than those with Fas-negative carcinoma while FasL did not influence patient outcome. These relationships indicate that benign and malignant mammary lesions are characterized by differential cellular expression of Fas and FasL and suggest that a neoplastic Fas negative/FasL positive phenotype may be linked to breast cancer progression. (C) 2000 Wiley-Liss, Inc.

AB - The Fas ligand (FasL) and its receptor Fas (APO-I or CD95) are members, respectively, of the tumor necrosis factor family that, upon interaction with each other, play a key role in the initiation of one apoptotic pathway. Faulty regulation of the Fas system has been described in a variety of human tumors with different histogenetic origin. Here, we describe the expression and distribution of Fas receptor and ligand pair antigens in surgical samples collected from a cohort of 186 patients bearing breast neoplasms (45 benign and 141 malignant lesions). Immunoperoxidase staining of formalin-fixed tissues showed that 91.1% of benign lesions expressed Fas, which was present in only 56.7% of malignant tumors. On the other hand, FasL was found positive in 22.2% of benign neoplasms and up-regulated in in situ as well as invasive carcinomas (53.9%). Moreover, in malignant tumors, the expression of receptor and ligand antigens appeared to be inversely related. When these findings were correlated with pathological parameters of prognostic relevance, a significant association was observed between FasL and the presence of metastatic lymph nodes and larger tumor size while Fas expression correlated to node-negative status and smaller tumor size. Patients with Fas positive tumors exhibited longer disease-free survival than those with Fas-negative carcinoma while FasL did not influence patient outcome. These relationships indicate that benign and malignant mammary lesions are characterized by differential cellular expression of Fas and FasL and suggest that a neoplastic Fas negative/FasL positive phenotype may be linked to breast cancer progression. (C) 2000 Wiley-Liss, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034688912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034688912&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 127

EP - 132

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -